At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 220 enrolled
Drug / intervention
BMS-986165 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating BMS-986165 and Placebo for Psoriasis. Completed, enrolled 220 participants across 34 sites in 3 countries.
Detailed Summary
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesChina, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartNov 2019
Primary CompletionMar 2021
Study CompletionJan 2022
TodayJul 2026
First PostedNov 18, 2019
Enrollment StartNov 25, 2019
Primary CompletionMar 8, 2021
Study CompletionJan 7, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.6 years ago
Interventions
BMS-986165drug
Specified dose on Specified Days
Placeboother
Specified dose on Specified days